Biopharmaceutical company, Collegium Pharmaceutical, Inc., with a market capitalization of USD 928.59 million, has initiated a USD 25 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC. The company will have USD 65 million remaining in its repurchase initiative. 

Collegium Pharmaceutical has set optimistic revenue guidance for 2025, projecting net product revenues between USD 735 million and USD 750 million. The company expects Jornay PM to generate over USD 135 million in revenue, with adjusted EBITDA anticipated to grow by 10 percent. In terms of strategic initiatives, the company recently expanded its ADHD sales force, adding 55 new representatives to enhance prescription growth.

Collegium will pay USD 25 million to Jefferies LLC and initially receive 692,281 shares under the ASR agreement. These shares are based on Collegium’s common stock closing price of USD 28.89 on May 9, 2025, representing about 80 percent of the expected total repurchased shares.

The ASR agreement, announced, follows a period of significant revenue growth for Collegium, with a 23 percent year-over-year increase in the first quarter of 2025. The company maintains impressive gross profit margins of 87.04 percent and has achieved revenue growth of 17.17 percent over the last twelve months.

The final number of shares will depend on the volume-weighted average prices of Collegium’s stock during the ASR term, with adjustments based on the ASR’s terms and conditions. The ASR is expected to conclude by the third quarter of 2025.

In other recent news, Collegium Pharmaceutical reported a strong financial performance for the first quarter of 2025, with net product revenues reaching USD 177.8 million, reflecting a 23 percent increase compared to the previous year. The company’s cash position also improved by USD 35 million from the end of 2024, highlighting its robust financial health.

Collegium announced a USD 25 million accelerated share repurchase program, reinforcing its commitment to shareholder value.